Applying Clinical Data to Practice in AMD

By Allen C. Ho, MD Chief Medical Editor and Robert L. Avery, MD Associate Medical Editor
 

Over the past 12 months, there have been many developments in regard to age-related macular degeneration (AMD). After positive 1-year data from the VIEW 1 and VIEW 2 trials were released, aflibercept (Eylea, Regeneron) was approved for neovascular AMD with labeling recommending less frequent injections than ranibizumab (Lucentis, Genentech) after 3 monthly loading doses. Subsequent 2- year data from the phase 3 trials held up the positive safety and efficacy evidence from year 1, although questions remain as to the long-term difference in treatment intervals between the 2 approved drugs with realworld dosing regimens.

The 1-year results from the CATT were also released at the Association for Research in Vision and Ophthalmology meeting in May 2011 and published in the New England Journal of Medicine. Although many of us were not surprised to learn that, with respect to visual outcome, bevacizumab (Avastin, Genentech) was found to be noninferior to ranibizumab, the prn arms did quite well when compared with the monthly arms. Additionally, the similarity of the duration of action of these 2 drugs could be seen as a surprise (albeit not a big surprise), as the molecular size of bevacizumab is significantly larger.

As the events of the past year suggest, the management of neovascular AMD will continue to evolve. We are fortunate to now have 2 approved and highly effective agents (as well as a seemingly equivalent off-label option) to treat this important age-related disease at a time when the population is aging. As molecular explorations yield new approaches and combination therapies and drug delivery devices hopefully demonstrate their safety and effectiveness in coming years, those of us in the retina subspecialty may have the opportunity to work together to devise more sustainable treatment regimens to combat this sightthreatening progressive disease.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Bryan Bechtel
Editor-in-Chief
484-581-1827
bbechtel@bmctoday.com

Alan B. Guralnick
Publisher
484-581-1832
aguralnick@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.

Website Design by Sides Media